2023 Education Partners:

Thank you for your support of our mission and vision for 2023!

Legislative Partner

X-Waiver Eliminated!

On December 29^th, 2022, with the signing of the Consolidated Appropriations Act of 2023, Congress eliminated the requirements related to the X-waiver for prescribing buprenorphine to treat opioid use disorder.  Medication for opioid use disorder assists those who are battling to overcome opioid use disorder by sustaining recovery and preventing overdoses. 

According to the Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA) announcements, effective immediately:

• Prescriptions for buprenorphine do not require an X-waiver number, only a standard DEA registration number.
• Limits on the number of patients a practitioner may treat with buprenorphine have been removed.

Clinicians with a current DEA registration number that includes Schedule III authority may now prescribe buprenorphine for opioid use disorder in accordance with their respective scope of practice and state regulations.  Later this year, SAMHSA and DEA plan to propose new training requirements related to prescribing and dispensing of buprenorphine for DEA registration.

The removal of the X-waiver stems from the Mainstreaming Addiction Treatment (MAT) Act, which was recently signed into law and aims to increase access to buprenorphine for treatment of opioid use disorder by expanding access. 

ASHP House of Delegate's New Hampshire 

Tonya Carlton, PharmD, BCPS, CPE

Elizabeth Wade, PharmD, BCPS, FASHP

Welcome to HOD Service for NH!

Alternate Delegate 2023:

Melanie McGuire, PharmD, BCCCP

COVID-19 Resource Center:

ASHP COVID 19 Resource Center Link